Alemtuzumab monotherapy for T-cell prolymphocytic leukemia: an observational study in Japan-Reference-Cited by-同舟云学术

Alemtuzumab monotherapy for T-cell prolymphocytic leukemia: an observational study in Japan

Published:2024 Issue: Volume: Page:
ISSN:1346-4280
Container-title:Journal of Clinical and Experimental Hematopathology
language:en
Short-container-title:JCEH

Author:

Yamaguchi Motoko¹,Fukuhara Noriko²,Takizawa Jun³,Ishitsuka Kenji⁴,Yokohama Akihiko⁵,Miyazaki Kana⁶,Nato Yuma¹,Ichikawa Satoshi²,Mitobe Masaki³,Shima Kodai⁴,Miyazawa Yuri⁵,Izutsu Koji⁷,Suzuki Ritsuro⁸,Nagai Hirokazu⁹,Nakamura Naoya¹⁰

Affiliation:

1. Department of Hematological Malignancies, Mie University Graduate School of Medicine, Tsu, Japan,

2. Department of Hematology, Tohoku University Hospital, Sendai, Japan,

3. Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan,

4. Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan,

5. Department of Hematology, Gunma University Graduate School of Medicine, Maebashi, Japan,

6. Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan,

7. Department of Hematology, National Cancer Center Hospital, Tokyo, Japan,

8. Department of Hematology and Oncology, Shimane University School of Medicine, Izumo, Japan,

9. Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan,

10. Department of Pathology, Tokai University, Isehara, Japan.

Publisher

Japanese Society for Lymphoreticular Tissue Research

Link

https://www.jstage.jst.go.jp/article/jslrt/advpub/0/advpub_24028/_pdf

Reference14 articles.

1. 1 Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36: 1720-1748.

2. 2 Pawson R, Dyer MJ, Barge R et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol. 1997; 15: 2667-2672.

3. 3 Dearden CE, Matutes E, Cazin B et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001; 98: 1721-1726.

4. 4 Keating MJ, Cazin B, Coutré S et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002; 20: 205-213.

5. 5 Jain P, Aoki E, Keating M et al. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). Ann Oncol. 2017; 28: 1554-1559.